IGlar U100

ApprovedSmall molecule

Novo Nordisk

IGlar U100 is one of 59 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

Type 1 DiabetesActive, not recruiting

Metabolic Dysfunction-Associated Steatotic Liver DiseaseActive, not recruiting

Type 2 Diabetes MellitusApproved

Active, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Metabolic Dysfunction-Associated Steatotic Liver DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

IGlar U100

Novo Nordisk

Approved

2 2

Byetta

AstraZeneca

Preclinical

20 3

Tanzeum

GSK

Preclinical

10 4

Insulin 320

Novo Nordisk

Preclinical

43 5

NOVOLIN R

Novo Nordisk

Preclinical

1 6

Adenocard

Astellas

Preclinical

1 7

Dostinex

Golytely

Cipro

Myrbetriq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

ApprovedActive, not recruiting

Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT07274644

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT03723772·66 enrolled

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

Effects of iGlarLixi Versus iGlar on Liver Fat Content in Patients With Type 2 Diabetes Mellitus With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial

Active, not recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Approved·NCT07274644·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IGlar U100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IGlar U100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IGlar U100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novo Nordisk

IGlar U100

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Type 1 Diabetes1 trial

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

References

Drug Info

Quick Facts

Related News